FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
1. Name and Address of Reporting Person* MORGENTHALER PARTNERS VII LP				2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) Other (specify below)				
50 PUBLIC SQUARE, SUITE 2700				3. Date of Earliest Transaction (Month/Day/Year) 10/28/2005											
(Street) CLEVELAND, OH 44113				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui					ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye	if Co	Code (Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)			Beneficia	nt of Securities ally Owned Following Transaction(s)		Ownership Form:	7. Nature of Indirect Beneficial Ownership	
	(A)		(A) or (D)	Price		oi (I (I			(Instr. 4)						
Common Stock 10/28/2005		10/28/2005		S	S 37,037 D \$ 2,272,345			I	See footnote (1)						
Reminder:	Report on a s	separate line fo	or each class of secur	·			Pers cont the f	ons whained i	no respon n this for splays a c	m are currei	not requ ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02
				Derivative Secur [e.g., puts, calls,							ly Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Execution Da (Year) any	4. Transactio Code (Instr. 8)	of Deri Secu Acq (A) Disp of (I	5. 6. D Number and		Date Exercisable Expiration Date onth/Day/Year)		Amo Und Secu	ttle and bunt of erlying trities r. 3 and	Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	Beneficia Ownersh (Instr. 4)
				Code V	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MORGENTHALER PARTNERS VII LP 50 PUBLIC SQUARE SUITE 2700 CLEVELAND, OH 44113		X				
Christoffersen Ralph E 4430 ARAPAHOE AVENUE SUITE 200 BOULDER, CO 80303	X					

Signatures

Theodore A. Laufik	10/31/2005
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 (1) The shares are held by Morgenthaler VII, LP (MPVII). Ralph E. Christoffersen, a director of Threshold Pharmaceuticals, Inc., is a Partner of Morgenthaler Management
- Parnters VII, LLC (MMPVII), the managing parnter of MPVII. Dr. Christoffersen shares voting power over the shares with the other members of MMPVII. The natural (1) persons who have voting or investment power over the shares held of record of MPVII are Robert C. Bellas, Jr., Greg E. Blonder, James W. Broderick, Ralph E. Christoffersen, Andrew S. Lanza, Theodore A. Laufik, Paul H. Levine, Gary R. Little, John D. Lutsi, Gary J. Morgenthaler, Robert D. Pavey, G. Gary Shaffer and Peter G. Taft. Dr. Christoffersen disclaims bemeficial ownership of the shares held by MPVII except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.